Preferred Label : tislelizumab;
UNII : 0KVO411B3N;
Origin ID : C000707970;
UMLS CUI : C4733463;
ATC code(s)
Currated CISMeF NLP mapping
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
Semantic type(s)
UMLS correspondences (same concept)
https://www.ema.europa.eu/en/medicines/human/EPAR/tevimbra
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
tislelizumab
tislelizumab
tislelizumab
orphan drug production
drug approval
europe
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
Esophageal Squamous Cell Carcinoma
neoplasm metastasis
Metastatic Esophageal Squamous Cell Carcinoma
Unresectable Esophageal Squamous Cell Carcinoma
Refractory Esophageal Squamous Cell Carcinoma
adult
infusions, intravenous
risk management
product surveillance, postmarketing
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical
---
https://ansm.sante.fr/tableau-marr/tislelizumab
2024
false
false
false
France
French
risk management
tislelizumab
tislelizumab
patient education handout
patients guideline
drug information
Drug-Related side effects and adverse reactions
signs and symptoms
Pneumonitis
colitis
hepatitis
endocrine system diseases
drug eruptions
nephritis
Infusion-Related Reaction
---
https://www.has-sante.fr/jcms/p_3544491/fr/tevimbra-tislelizumab-carcinome-epidermoide-de-l-oesophage
2024
false
false
false
France
adult
tislelizumab
treatment outcome
insurance, health, reimbursement
Antineoplastic Agents, Immunological
evaluation of the transparency committee
Esophageal Squamous Cell Carcinoma
tislelizumab
---
https://www.ema.europa.eu/en/medicines/human/EPAR/tizveni
2024
false
false
false
Netherlands
French
English
drug approval
europe
tislelizumab
tislelizumab
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
tislelizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
carcinoma, non-small-cell lung
adult
antineoplastic combined chemotherapy protocols
infusions, intravenous
programmed cell death 1 receptor
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
---